A Phase 4 interventional study of Idelalisib in Lymphoid Malignancies, sponsored by Gilead Sciences. Terminated at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to provide idelalisib to participants receiving GS-9820 in Gilead-sponsored Study GS-US-315-0102 at the time of study closure.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive idelalisib until unacceptable toxicity, disease progression, study discontinuation, or death occurs.
Drug: Idelalisib
Idelalisib 150 mg tablet administered orally twice daily
Also known as: Zydelig®
Number of Participants Experiencing Treatment-Emergent ≥ Grade 3 Adverse Events, Serious Adverse Events (SAEs), and Deaths
The severity of Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. An SAE was defined as an event that, at any dose, resulted in one or more of the following: 1) Death, 2) Life-threatening, 3) In-patient hospitalization or prolongation of existing hospitalization, 4) Persistent or significant disability/incapacity, 5) A congenital anomaly/birth defect, or 6) A medically important event or reaction.
Time frame: Up to Day 602 plus 30 days
Participants were enrolled at study sites in the Netherlands. The first participant was screened on 04 May 2016. The last study visit occurred on 28 December 2017.
| Milestone | Idelalisib |
|---|---|
| Started | 3 |
| Completed | 0 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Study terminated by sponsor | 2 |
The severity of Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. An SAE was defined as an event that, at any dose, resulted in one or more of the following: 1) Death, 2) Life-threatening, 3) In-patient hospitalization or prolongation of existing hospitalization, 4) Persistent or significant disability/incapacity, 5) A congenital anomaly/birth defect, or 6) A medically important event or reaction.
| Participants | Idelalisib |
|---|---|
| ≥ Grade 3 Adverse Event | 1 |
| SAE | 1 |
| Death | 0 |
Collected over Up to Day 602 plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Idelalisib |
|---|---|
| CholangitisHepatobiliary disorders | 1/3 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 1/3 |
| Event | Idelalisib |
|---|---|
| Urinary tract infectionInfections and infestations | 3/3 |
| AnaemiaBlood and lymphatic system disorders | 1/3 |
| Vision blurredEye disorders | 1/3 |
| Abdominal distensionGastrointestinal disorders | 1/3 |
| ConstipationGastrointestinal disorders | 1/3 |
| DiarrhoeaGastrointestinal disorders | 1/3 |
| Dry mouthGastrointestinal disorders | 1/3 |
| NauseaGastrointestinal disorders | 1/3 |
| FatigueGeneral disorders | 1/3 |
| Influenza like illnessGeneral disorders | 1/3 |
Safety Analysis Set: participants who took at least 1 dose of study drug.
| Age, Customized(Participants) | Idelalisib |
|---|---|
| From 65 - 84 years | 3 |
| Sex: Female, Male(Participants) | Idelalisib |
|---|---|
| Female | 2 |
| Male | 1 |
| Race and Ethnicity Not Collected(Participants) | Idelalisib |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from May 2016 to primary completion in Dec 2017, 19 months.
Results were first posted in Jan 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib